How effective is erdafitinib? Patient survival and response rate data

Erdafitinib is an oral fibroblast growth factor receptor (FGFR) inhibitor, mainly used to treat locally advanced or metastatic urothelial carcinoma (a type of bladder cancer) carrying FGFR2 or FGFR3 gene mutations. Its efficacy has been verified in clinical trials, especially for patients who have failed chemotherapy, erdafitinib provides a new treatment option. According to BLC2001pivotal clinical trial data, the objective response rate (ORR) of erdafitinib is 40%, of which 3% was a complete response (CR), and 37% was a partial response (PR). In addition, the disease control rate (DCR) reached 79%, indicating that most patients can achieve disease stabilization or remission after treatment.

In terms of survival, data from the BLC2001 trial showed that the median progression-free survival (PFS) of patients using erdafitinib was 5.5 months, and the median overall survival (OS) was 9.0 months. Compared with traditional chemotherapy, erdafitinib provides better survival benefit for patients with FGFR mutations, especially for patients who fail first-line chemotherapy. More importantly, among patients treated with erdafitinib, some individuals with FGFR mutations showed longer-lasting effects, and some patients survived for more than one year.

In terms of patient feedback, erdafitinib is relatively well tolerated, but it still has side effects such as hyperphosphatemia, oral ulcers, fatigue, diarrhea, and ocular toxicity. Clinical data shows that approximately 77% of patients will develop varying degrees of hyperphosphatemia, which can be controlled through dietary adjustments or phosphate binders. Because erdafitinib may affect retinal health, patients will need regular eye exams during treatment to monitor for potential eye complications.

Overall, erdafitinib is effective inFGFRIt has a good therapeutic effect in patients with mutated bladder cancer and can significantly improve the response rate and survival time. Although its efficacy is not as good as the long-term survival benefit of immunotherapy in some patients, erdafitinib is an effective personalized treatment option for people with specific genetic mutations. As more clinical studies are conducted, its use strategy may be further optimized in the future to improve the long-term survival rate and quality of life of patients.

Reference link:https://www.balversa.com/